预测轻度认知障碍向阿尔茨海默病转化的生物标志物的研究进展

Recent advance in biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer's disease

轻度认知障碍(MCI)被认为是痴呆的前期阶段,每年有10%~15%的MCI最终发展为痴呆。阿尔茨海默病(AD)是痴呆的首要病因,也是多数MCI的转归结局。早期识别出具有转化为AD高风险的MCI并进行干预,对控制认知障碍进展具有重要意义。笔者现从体液、影像学、遗传学这3个层面,对预测MCI向AD转化的核心和新型生物标志物的研究进展进行归纳,以期为MCI的转归预测或AD的早期诊断研究提供帮助。

Mild cognitive impairment(MCI)is considered to be the early stage of dementia.About 10%-15%of MCI patients eventually develop dementia each year.Alzheimer's disease(AD)is the leading cause of dementia,and also the final outcome of most MCI.Early identification and intervention of MCI with high risk of conversion to AD is of great significance for controlling the progress of cognitive impairment.The author summarizes the latest research progress of core and other new biomarkers that predict the conversion of MCI to AD from levels of body fluid,imaging and genetics,to provide guidance for predicting the outcomes of MCI or early diagnoses of AD.